Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: TAK-981 is a highly effective and selective inhibitor of the small ubiquitin-like modifier (SUMO) activating enzyme, and it promotes the expression of type I interferons (IFN-Is). Developing a sensitive bioanalytical assay for quantitating TAK-981 is essential in the clinical investigations for oncology drug development.
Materials & Methods: TAK-981 and its stable isotope labeled compound (TAK-981C, N) as the internal standard were employed in this LC-MS/MS assay.
Results: This assay was successfully validated from 0.1 ng/mL to 100 ng/mL with good accuracy and precision and has been applied to support clinical studies.
Conclusion: A sensitive and robust LC-MS/MS assay was validated for TAK-981 in human plasma for the first time.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367096 | PMC |
| http://dx.doi.org/10.1080/17576180.2025.2518048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pet dogs spontaneously develop a form of diffuse large B cell lymphoma (DLBCL) that recapitulates many of the features of double hit () human DLBCL. We recently completed a clinical trial in dogs with DLBCL using a combination of canine anti-CD20 antibody and low dose doxorubicin followed by one of three small molecule immune-modulating agents (KPT-9274, TAK-981 or RV1001). Clinical outcomes and tumor specific biomarkers of response from these dogs have been previously reported.
View Article and Find Full Text PDFTargeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis.
EMBO J
August 2025
Cancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Synovial sarcoma (SySa) is an aggressive soft tissue sarcoma with an urgent need to develop targeted therapies. Here, we exploited specific vulnerabilities created by transcriptional rewiring by the fusion protein SS18::SSX, the sole oncogenic driver in SySa. To uncover genes that are selectively essential for the fitness of SySa cells compared to other tumor cell lines, we mined the Cancer-Dependency-Map data.
View Article and Find Full Text PDFSUMOylation Regulates Neutrophil Phagocytosis and Migration.
Pharmaceuticals (Basel)
July 2025
Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA.
: Accumulating evidence indicates that neutrophils undergo reprogramming of their effector functions as they migrate from the bloodstream into an inflamed tissue. Here, we examined the role of the small ubiquitin-like modifier (SUMO) conjugation in modulating neutrophil functional changes in the inflammatory microenvironment. : Primary human and murine neutrophils were used to assess SUMOylation levels in vitro by Western blotting and results were validated in clinical samples from patients undergoing surgery involving hypothermic circulatory arrest.
View Article and Find Full Text PDFSynthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs growth and chemosensitizes embryonal and alveolar rhabdomyosarcoma cell lines.
Mol Cell Biochem
June 2025
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Rhabdomyosarcoma (RMS) is a highly aggressive pediatric soft tissue sarcoma with limited therapeutic options, particularly for cases resistant to conventional treatments. The SUMOylation pathway, which plays a key role in regulating the cell cycle, apoptosis, and transcription, has emerged as a potential therapeutic target in RMS. Elevated levels of SUMO1 and SUMO2/3 conjugates in RMS cell lines, compared to normal human skeletal muscle cells, underscore the association between upregulated SUMOylation and aggressive cancer phenotypes.
View Article and Find Full Text PDFQuantitation of TAK-981 in human plasma via LC-MS/MS and its application in clinical trials.
Bioanalysis
June 2025
Takeda Development Center Americas, Inc, Cambridge, MA, USA.
Aim: TAK-981 is a highly effective and selective inhibitor of the small ubiquitin-like modifier (SUMO) activating enzyme, and it promotes the expression of type I interferons (IFN-Is). Developing a sensitive bioanalytical assay for quantitating TAK-981 is essential in the clinical investigations for oncology drug development.
Materials & Methods: TAK-981 and its stable isotope labeled compound (TAK-981C, N) as the internal standard were employed in this LC-MS/MS assay.